Sarah Buchan

Dr. Sarah Buchan is a Canadian epidemiologist and specialist in vaccine-preventable diseases based in Toronto, Ontario.

Education

Career and Affiliations

Public Health Ontario

Buchan is a scientist at Public Health Ontario (PHO) in Health Protection where she conducts applied public health research related to the epidemiology of vaccine-preventable and other infectious diseases.1) She has been supporting PHO’s COVID-19 Incident Management System since February 2020, with a focus on addressing questions to support the provincial response and inform decision-making. She has also contributed to analyses related to COVID-19 burden, transmission, variants of concern, immunization, and vaccine effectiveness.2)

University of Toronto

Buchan is an assistant professor at the Dalla Lana School of Public Health and the Institute for Pandemics at the University of Toronto.3) 4)

ICES

Buchan is an adjunct scientist at the Institute for Clinical Evaluative Sciences (ICES).5)

Ontario COVID-19 Science Advisory Table

Buchan is a member of the Modelling Consensus Table of the Ontario COVID-19 Science Advisory Table.6)

Research

Buchan's work around 2016 was supported by a Canadian Immunization Research Network Trainee Award, including a study of influenza vaccines and vaccine hesitancy.7)

Areas of Focus

RSV

In 2018, Buchan co-authored a paper on RSV funded by the U.S. Centers for Disease Control and Prevention (CDC) through their Achieving Public Health Impact through Research program.8)

She's also received funding from SickKids.9)

Influenza

Buchan received a $202,725 grant from ICESs in 2018 for a project titled “Influenza vaccines, statins, and laboratory-confirmed influenza outcomes in older adults: can vaccines and statins reduce the burden of influenza?”10)

COVID-19

Buchan published a study examining adverse events related to COVID-19 vaccines, funded by the Canadian Immunization Research Network (CIRN), Public Health Agency of Canada and the Canadian Institutes of Health Research (CIHR).11)

Previously, she co-authored a study titled “Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study”.12) This also received funding from the CIRN, PHAC and CIHR, as well as the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force, and the Ontario Health Data Platform.

She also contributed to a study on treatments for COVID-19, funded by the COVID-19 Emergency Response Fund from the Ottawa Hospital.13)

1)
Dr. Sarah Buchan. (2021, September 10). Public Health Ontario. https://archive.ph/H0PNH
2)
Occupational and Environmental Health Seminar: “Exploring COVID-19 cases and outbreaks by industry.” (2022, February 24). Dalla Lana School of Public Health. https://archive.ph/PrWGb
3)
Buchan, Sarah A. Dalla Lana School of Public Health. Retrieved May 11, 2022, from https://archive.ph/BoXgQ
4)
Sarah Buchan. Institute for Pandemics. Retrieved May 12, 2022, from https://archive.ph/8GPdK
5) , 10)
Sarah Buchan. ICES. Retrieved May 12, 2022, from https://archive.ph/jX5By
6)
Our Partners. Ontario COVID-19 Science Advisory Table. Retrieved May 9, 2022, from https://web.archive.org/web/20220509143427/https://covid19-sciencetable.ca/our-partners/
7)
Buchan, S. A., & Kwong, J. C. (2016). Trends in influenza vaccine coverage and vaccine hesitancy in Canada, 2006/07 to 2013/14: results from cross-sectional survey data. CMAJ Open, 4(3), E455–E462. https://doi.org/10.9778/cmajo.20160050
8)
Regan, A. K., Klein, N. P., Langley, G., Drews, S. J., Buchan, S., Ball, S., Kwong, J. C., Naleway, A., Thompson, M., Wyant, B. E., Levy, A., Chung, H., Feldman, B., Katz, M. A., Azziz-Baumgartner, E., Shifflet, P., Fink, R. V., Fell, D., Riesel, D., & Mandelboim, M. (2018). Respiratory Syncytial Virus Hospitalization During Pregnancy in 4 High-income Countries, 2010–2016. Clinical Infectious Diseases, 67(12), 1915–1918. https://doi.org/10.1093/cid/ciy439
11)
Nasreen, S., Calzavara, A., Buchan, S. A., Thampi, N., Johnson, C., Wilson, S. E., & Kwong, J. C. (2022). Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance. Vaccine. https://doi.org/10.1016/j.vaccine.2022.04.065
12)
Chung, H., He, S., Nasreen, S., Sundaram, M. E., Buchan, S. A., Wilson, S. E., Chen, B., Calzavara, A., Fell, D. B., Austin, P. C., Wilson, K., Schwartz, K. L., Brown, K. A., Gubbay, J. B., Basta, N. E., Mahmud, S. M., Righolt, C. H., Svenson, L. W., MacDonald, S. E., & Janjua, N. Z. (2021). Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ (Clinical Research Ed.), 374, n1943. https://doi.org/10.1136/bmj.n1943
13)
MacFadden, D. R., Brown, K., Buchan, S. A., Chung, H., Kozak, R., Kwong, J. C., Manuel, D., Mubareka, S., & Daneman, N. (2022). Screening Large Population Health Databases for Potential COVID-19 Therapeutics: A Pharmacopeia-Wide Association Study (PWAS) of Commonly Prescribed Medications. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofac156
Print/export